Financials Five-year financial record Consolidated income statement for the year ended 31 March 1 2 2012 2011 2010 2009 2008 m m m m m Revenue 197.0 111.4 98.5 84.8 75.0 Cost of sales 56.3 34.1 32.8 37.1 32.1 Gross profit 140.7 77.3 65.7 47.7 42.9 Operating and administrative expenses 46.3 45.3 29.3 20.6 13.8 Restructuring costs 1.1 3.8 0.7 10.9 8.1 Operating expenses 47.4 49.1 28.6 31.5 21.9 Research and development 39.7 32.1 26.7 21.2 12.2 Share of results of associates 0.3 0.4 0.7 Research and development expenses 39.7 32.1 27.0 21.6 12.9 Profit on disposal of assets and investments 0.2 1.5 1.1 2.6 0.4 Amounts written off associates and investments 0.2 1.4 3.4 Amounts written off property, plant and equipment 3.0 Amortisation and impairment of business combination intangibles 30.7 10.0 9.1 3.0 Operating profit loss 19.9 13.8 2.1 9.2 8.5 Net financial income 3.1 3.0 7.0 2.1 2.2 Profit loss before tax 23.0 10.8 9.1 11.3 10.7 Tax 8.4 20.0 2.2 1.8 1.9 Profit loss after tax for the year 14.6 9.2 11.3 13.1 8.8 Earnings loss per share Basic 4.5p 3.4p 4.4p 7.1p 5.9p Diluted 4.4p 3.4p 4.4p 7.1p 5.9p Gross profit 1 2 2012 2011 2010 2009 2008 m m m m m Royalties from launched products 51.3 43.2 38.0 32.1 24.9 Income from new agreements and milestone payments 5.0 4.5 8.6 11.0 18.0 Gross profit from marketed products 58.0 26.6 19.1 4.6 Gross profit from Biocompatibles 26.4 3.0 Gross profit 140.7 77.3 65.7 47.7 42.9 1 The results for the year ended 31 March 2011 include the results of Biocompatibles International plc from the date of acquisition, being 27 January 2011.
2 The results for the year ended 31 March 2009 include the results of Protherics PLC from the date of acquisition, being 4 December 2008.
2 The statement of financial position for 31 March 2009 includes the assets and liabilities acquired from Protherics PLC during the year.
Consolidated cash flow statement for the year ended 31 March 1 2 2012 2011 2010 2009 2008 m m m m m Net cash from used in operating activities 47.2 12.0 5.8 1.8 13.4 Net cash used in from investing activities 3.9 5.5 2.6 21.8 0.8 Net cash used in from financing activities 0.2 0.6 1.4 0.1 Increase decrease in cash and cash equivalents 43.1 18.1 4.6 19.9 14.2 Effect of exchange rate fluctuations on cash held 0.1 0.8 0.2 1.3 0.2 Cash and cash equivalents at start of year 63.7 82.6 78.2 57.0 43.0 Cash and cash equivalents at end of year 106.9 63.7 82.6 78.2 57.0 1 The results for the year ended 31 March 2011 include the results of Biocompatibles International plc from the date of acquisition, being 27 January 2011.
140 Financials BTG plc Annual Report and Accounts 2012
